Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension

Abstract

Alterations in metabolism and bioenergetics are hypothesized in the mechanisms leading to pulmonary vascular remodeling and heart failure in pulmonary hypertension (PH). To test this, we performed metabolomic analyses on 30 PH individuals and 12 controls. Furthermore, using 2‐[18F]fluoro‐2‐deoxy‐D‐glucose positron emission tomography, we dichotomized PH patients into metabolic phenotypes of high and low right ventricle (RV) glucose uptake and followed them longitudinally. In support of metabolic alterations in PH and its progression, the high RV glucose group had higher RV systolic pressure (p < 0.001), worse RV function as measured by RV fractional area change and peak global longitudinal strain (both p < 0.05) and may be associated with poorer outcomes (33% death or transplantation in the high glucose RV uptake group compared to 7% in the low RV glucose uptake group at five years follow‐up, log‐ranked p = 0.07). Pathway enrichment analysis identified key metabolic pathways including fructose catabolism, arginine‐nitric oxide metabolism, tricarboxylic acid cycle, and ketones metabolism. Integrative human protein‐protein interactome network analysis of metabolomic and transcriptomic data identified key pathobiological pathways: arginine biosynthesis, tricarboxylic acid cycle, purine metabolism, hypoxia‐inducible factor 1, and apelin signaling. These findings identify a PH metabolomic endophenotype, and for the first time link this to disease severity and outcomes.

Keywords

• metabolomics
• arginine
• tricarboxylic acid cycle
• FDG‐PET scan
• outcomes